hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; wherein the light chain variable domain of (a) comprises d. i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ IDNO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and the heavy chain variable domain of (b) comprises: e. i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0007c] In yet another aspect, the disclosure refers to the use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject, comprising that the subject is to be administered a dose of 210 mg at an interval of every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0007d] In yet another aspect, the disclosure refers to the use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject, comprising that the subject is to be administered a dose of 210 mg at an interval of every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; wherein the light chain variable domain of (a) comprises d. i. a light chain CDR1 sequence comprising the

weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; wherein the light chain variable domain of (a) comprises d. i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ IDNO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and the heavy chain variable domain of (b) comprises: e. i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8.

[0007h] In a still further aspect, the disclosure refers to the use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for reducing ACQ-6 score in a subject, comprising that the subject is to be administered a dose of 70 mg to 280 mg at an interval of every 2 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0007i] In a still further aspect, the disclosure refers to the use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for reducing ACQ-6 score in a subject, comprising that the subject is to be administered a dose of 70 mg to 280 mg at an interval of every 2 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence

that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; wherein the light chain variable domain of (a) comprises d. i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ IDNO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and the heavy chain variable domain of (b) comprises: e. i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8.

[0007j] In a still further aspect, the disclosure refers to the use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject having a non-eosinophilic profile or a low eosinophil profile, comprising that the subject is to be administered said anti-TSLP antibody or antigen binding fragment thereof in a dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody or antigen binding fragment binding to TSLP inhibits TSLP activity, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises A. a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0007k] In a still further aspect, the disclosure refers to the use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject having a Th2 low profile, comprising that the subject is to be administered said anti-TSLP antibody or antigen binding fragment thereof in a dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks,wherein the antibody or antigen binding fragment binding to TSLP inhibits TSLP activity, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises A. a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set

forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0007l] In a still further aspect, the disclosure refers to the use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for reducing ACQ-6 score in a subject having a low eosinophil profile, comprising that the subject is to be administered said anti-TSLP antibody or antigen binding fragment thereof in a dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody or antigen binding fragment binding to TSLP inhibits TSLP activity, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises A. a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0007m] In a still further aspect, the disclosure refers to the use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for reducing ACQ-6 score in a subject having a Th2 low profile, comprising that the subject is to be administered said anti-TSLP antibody or antigen binding fragment thereof in a dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks,wherein the antibody or antigen binding fragment to TSLP inhibits TSLP activity, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises A. a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0008] The disclosure provides a method for treating asthma in a subject comprising administering a therapeutically effective amount of an anti-TSLP antibody or antibody variant in a

WHAT IS CLAIMED:

1. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject, comprising that the subject is to be administered a dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

2. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject, comprising that the subject is to be administered a dose of 70 mg to 280 mg at an interval of every two weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9;

c. wherein the light chain variable domain of (a) comprises

d. i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

the heavy chain variable domain of (b) comprises:

e. i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8,

wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

3. The use of any one of claims 1 or 2 wherein the antibody or antigen binding fragment is to be administered every 4 weeks.

4. The use of any one of claims 1 to 3 wherein the antibody or antigen binding fragment is to be administered at a dose of 70 mg.

5. The use of any one of claims 1 to 3 wherein the antibody or antigen binding fragment is to be administered at a dose of 210 mg.

6. The use of any one of claims 1 to 3 wherein the antibody or antigen binding fragment is to be administered at a dose of 280 mg.

7. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject, comprising that the subject is to be administered a dose of 210 mg at an interval of every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

8. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject, comprising that the subject is to be administered a dose of 210 mg at an interval of every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9;

c. wherein the light chain variable domain of (a) comprises

d. i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ IDNO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

the heavy chain variable domain of (b) comprises:

e. i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8,

wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

9. The use of any one of the preceding claims wherein the antibody or antigen binding fragment is to be administered for a period of at least 4 months, 6 months, 9 months, 1 year or more.

10. The use of any one of the preceding claims, wherein said anti-TSLP antibody or antigen binding fragment thereof is bivalent and selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single chain antibody, a monomeric antibody, a diabody, a triabody, a tetrabody, a Fab fragment, , an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody.

11. The use of claim 8, wherein said anti-TSLP antigen binding fragment is selected from the group consisting of a diabody, a triabody, a tetrabody, and a Fab fragment, wherein the dose is adjusted such that the binding sites to be equimolar to the those dosed by bivalent antibodies.

12. The use of any one of the preceding claims, wherein the antibody is an IgG2 antibody.

13. The use of any one of the preceding claims, wherein the antibody or antigen binding fragment is a human antibody.

14. The use of any one of the preceding claims wherein, the medicament comprises a pharmaceutically acceptable carrier or excipient.

15. The use of any one of the preceding claims wherein, wherein the asthma is severe asthma.

16. The use of any one of the preceding claims, wherein the asthma is eosinophilic or non-eosinophilic asthma.

17. The use any one of the preceding claims, wherein the asthma is low eosinophil asthma.

18. The use of any one of the preceding claims, wherein the subject is an adult.

19. The use of any one of the preceding claims, wherein the subject is a child or adolescent.

20. The use of any one of the preceding claims, wherein the administration decreases eosinophils in blood, sputum, broncheoalveolar fluid, or lungs of the subject.

21. The use of any one of the preceding claims, wherein the administration shifts cell counts in the subject from a Th2 high population to a Th2 low population.

22. The use of any one of the preceding claims, wherein the administration improves one or more measures of asthma in a subject selected from the group consisting of

forced expiratory volume (FEV), FEV_1 reversibility, forced vital capacity (FCV), FeNO, Asthma Control Questionnaire-6 score and AQLQ(S)+12 score.

23. The use of any one of the preceding claims, wherein the administration improves one or more symptoms of asthma as measured by an asthma symptom diary.

24. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject, comprising that the subject is to be administered a dose of 70 to 280 mg at an interval of every 2 weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2, wherein the antibody is an IgG2 antibody.

25. The use of claim 24 wherein the antibody is to be administered every 4 weeks.

26. The use of claim 24 or 25 wherein the antibody is to be administered at a dose of 70 mg.

27. The use of any one of claims 24 to 25 wherein the antibody is to be administered at a dose of 210 mg.

28. The use of any one of claims 24 to 25 wherein the antibody is to be administered at a dose of 280 mg.

29. The use of any one of the preceding claims wherein the antibody is tezepelumab.

30. The use of claim 29 wherein the antibody is an IgG2 antibody, and has the full length heavy and light chain sequences set out in SEQ ID NOs: 105 and 106, respectively.

31. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for reducing the frequency of asthma exacerbation in a subject, comprising that the subject is to be administered a dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

32. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for reducing the frequency of asthma exacerbation in a subject, comprising that the subject is to be administered dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9;

c. wherein the light chain variable domain of (a) comprises

d. i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ IDNO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

the heavy chain variable domain of (b) comprises:

e. i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8.

33. The use of any one of claims 31 to 32, wherein the antibody or antigen binding fragment is to be administered every 4 weeks.

34. The use of any one of claims 31 to 32wherein the antibody or antigen binding fragment is to be administered at a dose of 70 mg.

35. The use of any one of claims 31 to 32 wherein the antibody or antigen binding fragment is to be administered at a dose of 210 mg.

36. The use of any one of claims 31 to 32wherein the antibody or antigen binding fragment is to be administered at a dose of 280 mg.

37. The use of any one of claims 31 to 36 wherein the antibody or antigen binding fragment is to be administered for a period of at least 4 months, 6 months, 9 months, 1 year or more.

38. The use of any one of claims 31 to 37, wherein said anti-TSLP antibody or antigen binding fragment thereof is selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single chain antibody, a monomeric antibody, a diabody, a triabody, a tetrabody, a Fab fragment, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody .

39. The use of any one of claims 31 to 38, wherein antibody or antigen binding fragment thereof is an IgG2 antibody.

40. The use of any one of claims 31 to 39, wherein the antibody or antigen binding fragment thereof is a human antibody.

41. The use of any one of claims 31 to 40 wherein, the medicament further comprises a pharmaceutically acceptable carrier or excipient.

42. The use of any one of claims 31 to 41 wherein the administration delays the time to an asthma exacerbation compared to a subject not receiving the anti-TSLP antibody.

43. The use of any one of claims 31 to 42 wherein the administration reduces frequency of or levels of co-administered therapy in the subject.

44. The use of claim 43 wherein the co-administered therapy is inhaled corticosteroids (ICS), long-acting β2 agonist (LABA), leukotriene receptor antagonists (LTRA), long-acting anti-muscarinics (LAMA),cromones, short- acting β2 agonist (SABA), and theophylline or oral corticosteroids.

45. The use of claim 43, wherein the administration eliminates the need for corticosteroid therapy.

46. The use of any one of the preceding claims wherein the administration is subcutaneous or intravenous.

47. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for reducing ACQ-6 score in a subject, comprising that the subject is to be administered a dose of 70 mg to 280 mg at an interval of every 2 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

48. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for reducing ACQ-6 score in a subject, comprising that the subject is to be administered a dose of 70 mg to 280 mg at an interval of every 2 weeks, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9;

c. wherein the light chain variable domain of (a) comprises

d. i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ IDNO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

the heavy chain variable domain of (b) comprises:

e. i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8.

49. The use of any one of the preceding claims wherein the administration is subcutaneous or intravenous.

50. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject having a non-eosinophilic profile or a low eosinophil profile, comprising that the subject is to be administered said anti-TSLP antibody or antigen binding fragment thereof in a dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody or antigen binding fragment binding to TSLP inhibits TSLP activity, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

A. a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

51. The use of any one of claims 31 to 50 wherein the anti-TSLP antibody is tezepelumab.

52. The use of claim 51 wherein the antibody is an IgG2 antibody, and has the full length heavy and light chain sequences set out in SEQ ID NOs: 105 and 106, respectively.

53. The use of any one of claims 50, or 51 wherein the subject has an eosinophil count less than 250 cells/µL at start of treatment.

54. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for treating asthma in a subject having a Th2 low profile, comprising that the subject is to be administered said anti-TSLP antibody or antigen binding fragment thereof in a dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody or antigen binding fragment binding to TSLP inhibits TSLP activity, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

A. a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

55. The use of claim 54 wherein the subject has a Th2 profile of IgE less than or equal to 100 IU/ml or eosinophil count of less than 140 cells/µL at the time of diagnosis.

56. The use of claim 54 or 55 wherein the antibody is tezepelumab.

57. The use of claim 56 wherein the antibody is an IgG2 antibody, and has the full length heavy and light chain sequences set out in SEQ ID NOs: 105 and 106, respectively.

58. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for reducing ACQ-6 score in a subject having a low eosinophil profile, comprising that the subject is to be administered said anti-TSLP antibody or antigen binding fragment thereof in a dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody or antigen binding fragment binding to TSLP inhibits TSLP activity, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

A. a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

59. The use of claim 58 wherein the anti-TSLP antibody is tezepelumab.

60. The use of claim 59 wherein the antibody is an IgG2 antibody, and has the full length heavy and light chain sequences set out in SEQ ID NOs: 105 and 106, respectively.

61. The use of claims 58, or 59 wherein the subject has an eosinophil count less than 250 cells/μL at start of treatment.

62. Use of a therapeutically effective amount of an anti-TSLP antibody or antigen binding fragment thereof in the manufacture of a medicament for reducing ACQ-6 score in a subject having a Th2 low profile, comprising that the subject is to be administered said anti-TSLP antibody or antigen binding fragment thereof in a dose of 70 mg to 280 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody or antigen binding fragment binding to TSLP inhibits TSLP activity, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

A. a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

63. The use of claim 62 wherein the subject has a Th2 profile of IgE less than or equal to 100 IU/ml or eosinophil count of less than 140 cells/µL at the time of diagnosis.

64. The use of claims 62 or 63 wherein the antibody is tezepelumab.

65. The use of claim 64 wherein the antibody is an IgG2 antibody, and has the full length heavy and light chain sequences set out in SEQ ID NOs: 105 and 106, respectively.

66. The use of any one of claims 50-65 wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b),

wherein the light chain variable domain of (a) comprises

d. i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ IDNO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

the heavy chain variable domain of (b) comprises:

e. i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8,

wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

67. The use of any one of claims 50-66 wherein the antibody or antigen binding fragment thereof is to be administered every 4 weeks.

68. The use any one of claims 50-67 wherein the administration is subcutaneous or intravenous.